Candida parapsilosis complex in the clinical setting

1. Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl Med. 4, 165rv113 (2012).

   Google Scholar 

2. Hawksworth, D. L. & Lucking, R. Fungal diversity revisited: 2.2 to 3.8 million species. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.funk-0052-2016 (2017).

3. Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L. & Kullberg, B. J. Invasive candidiasis. Nat. Rev. Dis. Primers 4, 18026 (2018).

   Google Scholar 

4. Rolling, T. et al. Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species. Nat. Microbiol. 6, 1505–1515 (2021).

   CAS 
   PubMed Central 

   Google Scholar 

5. Zhai, B. et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat. Med. 26, 59–64 (2020).

   CAS 
   PubMed Central 

   Google Scholar 

6. Hoenigl, M. et al. COVID-19-associated fungal infections. Nat. Microbiol. 7, 1127–1140 (2022). This article provides an update on the epidemiology, clinical risk factors and predisposing features of the host environment of COVID-19-associated fungal infections.

   CAS 
   PubMed Central 

   Google Scholar 

7. Ramos-Martínez, A. et al. Impact of the COVID-19 pandemic on the clinical profile of candidemia and the incidence of fungemia due to fluconazole-resistant Candida parapsilosis. J. Fungi 8, 451 (2022).

   Google Scholar 

8. Prattes, J. et al. Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Med. 47, 1158–1160 (2021).

   CAS 
   PubMed Central 

   Google Scholar 

9. Krishna, V., Bansal, N., Morjaria, J. & Kaul, S. COVID-19-associated pulmonary mucormycosis. J. Fungi 8, 711 (2022).

   CAS 

   Google Scholar 

10. Asadzadeh, M. et al. High-resolution fingerprinting of Candida parapsilosis isolates suggests persistence and transmission of infections among neonatal intensive care unit patients in Kuwait. Sci. Rep. 9, 1340 (2019).

    PubMed Central 

    Google Scholar 

11. Mamali, V. et al. Increasing incidence and shifting epidemiology of candidemia in Greece: results from the first nationwide 10-year survey. J. Fungi 8, 116 (2022).

    CAS 

    Google Scholar 

12. Arastehfar, A. et al. Candidemia among coronavirus disease 2019 patients in Turkey admitted to intensive care units: a retrospective multicenter study. Open Forum Infect. Dis. 9, ofac978 (2022).

    Google Scholar 

13. Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M. & Jones, R. N. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open Forum Infect. Dis. 6, S79–S94 (2019).

    PubMed Central 

    Google Scholar 

14. Pfaller, M. A., Carvalhaes, C. G., DeVries, S., Rhomberg, P. R. & Castanheira, M. Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections. Med. Mycol. 60, myac028 (2022).

    CAS 
    PubMed Central 

    Google Scholar 

15. Diaz-Garcia, J. et al. Evidence of fluconazole-resistant Candida parapsilosis genotypes spreading across hospitals located in Madrid, Spain and harboring the Y132F ERG11p substitution. Antimicrob. Agents Chemother. 66, e0071022 (2022).

    Google Scholar 

16. Toth, R. et al. Candida parapsilosis: from genes to the bedside. Clin. Microbiol. Rev. 32, e00111-18 (2019). This review discusses C. parapsilosis pathogenesis, transcriptome studies and molecular mechanisms of virulence.

    PubMed Central 

    Google Scholar 

17. Nemeth, T. M. G., Gacser, A., Nosanchuk, J. D. A. in Encyclopedia of Mycology Vol. 1 526–543 (Elsevier, 2021).

18. Mixao, V. et al. Genome analysis of five recently described species of the CUG-Ser clade uncovers Candida theae as a new hybrid lineage with pathogenic potential in the Candida parapsilosis species complex. DNA Res. 29, dsac010 (2022).

    PubMed Central 

    Google Scholar 

19. Samantaray, S. & Singh, R. Evaluation of MALDI-TOF MS for identification of species in the Candida parapsilosis complex from candidiasis cases. J. Appl. Lab. Med. 7, 889–900 (2022).

    Google Scholar 

20. Krassowski, T. et al. Evolutionary instability of CUG-Leu in the genetic code of budding yeasts. Nat. Commun. 9, 1887 (2018).

    PubMed Central 

    Google Scholar 

21. Pountain, A. W., Collette, J. R., Farrell, W. M. & Lorenz, M. C. Interactions of both pathogenic and nonpathogenic CUG clade Candida species with macrophages share a conserved transcriptional landscape. mBio 12, e0331721 (2021).

    Google Scholar 

22. Gómez-Molero, E. et al. Phenotypic variability in a coinfection with three independent Candida parapsilosis lineages. Front. Microbiol. 11, 1994 (2020).

    PubMed Central 

    Google Scholar 

23. Pal, S. E. et al. A Candida parapsilosis overexpression collection reveals genes required for pathogenesis. J. Fungi 7, 97 (2021).

    CAS 

    Google Scholar 

24. Kulig, K. et al. Insight into the properties and immunoregulatory effect of extracellular vesicles produced by Candida glabrata, Candida parapsilosis, and Candida tropicalis biofilms. Front. Cell Infect. Microbiol. 12, 879237 (2022).

    CAS 
    PubMed Central 

    Google Scholar 

25. Yamin, D. H., Husin, A. & Harun, A. Risk factors of Candida parapsilosis catheter-related bloodstream infection. Front. Public Health 9, 631865 (2021).

    PubMed Central 

    Google Scholar 

26. Demirci-Duarte, S., Arikan-Akdagli, S. & Gulmez, D. Species distribution, azole resistance and related molecular mechanisms in invasive Candida parapsilosis complex isolates: increase in fluconazole resistance in 21 years. Mycoses 64, 823–830 (2021).

    CAS 

    Google Scholar 

27. Thomaz, D. Y. et al. Environmental clonal spread of azole-resistant Candida parapsilosis with Erg11-Y132F mutation causing a large candidemia outbreak in a Brazilian cancer referral center. J. Fungi 7, 259 (2021).

    CAS 

    Google Scholar 

28. Arastehfar, A. et al. Clonal candidemia outbreak by Candida parapsilosis carrying Y132F in Turkey: evolution of a persisting challenge. Front. Cell Infect. Microbiol. 11, 676177 (2021).

    CAS 
    PubMed Central 

    Google Scholar 

29. Thomaz, D. Y. et al. An azole-resistant Candida parapsilosis outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front. Microbiol. 9, 2997 (2018).

    PubMed Central 

    Google Scholar 

30. Daneshnia, F. et al. Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU. Emerg. Microbes Infect. 11, 2264–2274 (2022).

    CAS 
    PubMed Central 

    Google Scholar 

31. Cupozak-Pinheiro, W. J. et al. Candida species contamination in drinking groundwater from residence wells in three municipalities of midwestern Brazil and the potential human health risks. Microb. Pathog. 169, 105660 (2022).

    CAS 

    Google Scholar 

32. Prigitano, A. et al. Evolution of fungemia in an Italian region. J. Mycol. Med. 30, 100906 (2020).

    CAS 

    Google Scholar 

33. Matos, T. et al. Candidaemia in central slovenia: a 12-year retrospective survey. Mycoses 64, 753–762 (2021).

    CAS 

    Google Scholar 

34. Rodriguez, L. et al. A multi-centric study of Candida bloodstream infection in Lima-Callao, Peru: species distribution, antifungal resistance and clinical outcomes. PLoS ONE 12, e0175172 (2017).

    PubMed Central 

    Google Scholar 

35. Xiao, M. et al. Distribution and antifungal susceptibility of Candida species causing candidemia in China: an update from the CHIF-NET study. J. Infect. Dis. 221, S139–S147 (2020).

    Google Scholar 

36. Kajihara, T. et al. Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010–2019: a retrospective observational study based on national surveillance data. Med. Mycol. 60, myac071 (2022).

    PubMed Central 

    Google Scholar 

37. Arastehfar, A. et al. Epidemiology of candidemia in Shiraz, southern Iran: a prospective multicenter study (2016–2018). Med. Mycol. 59, 422–430 (2021).

    CAS 

    Google Scholar 

38. Khan, Z. et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS ONE 14, e0216250 (2019).

    PubMed Central 

    Google Scholar 

39. Beyer, R. et al. Antifungal susceptibility of yeast bloodstream isolates collected during a 10-year period in Austria. Mycoses 62, 357–367 (2019).

    CAS 

    Google Scholar 

40. Risum, M. et al. Update 2016–2018 of the nationwide Danish Fungaemia Surveillance Study: epidemiologic changes in a 15-year perspective. J. Fungi 7, 491 (2021).

    Google Scholar 

41. Machado, M. et al. Incidence of candidemia is higher in COVID-19 versus non-COVID-19 patients, but not driven by intrahospital transmission. J. Fungi 8, 305 (2022).

    CAS 

    Google Scholar 

42. Routsi, C. et al. Epidemiology of candidemia and fluconazole resistance in an ICU before and during the COVID-19 pandemic era. Antibiotics 11, 771 (2022).

    CAS 
    PubMed Central 

    Google Scholar 

43. Brescini, L. et al. Candidemia in internal medicine: facing the new challenge. Mycopathologia 187, 181–188 (2022).

    PubMed Central 

    Google Scholar 

44. Barchiesi, F. et al. Factors related to outcome of bloodstream infections due to Candida parapsilosis complex. BMC Infect. Dis. 16, 387 (2016).

    PubMed Central 

    Google Scholar 

45. Siopi, M. et al. Epidemiological trends of fungemia in Greece with a focus on candidemia during the recent financial crisis: a 10-year survey in a tertiary care academic hospital and review of literature. Antimicrob. Agents Chemother. 64, e01516-19 (2020).

    PubMed Central 

    Google Scholar 

46. Almirante, B. et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case–control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 44, 1681–1685 (2006).

    PubMed Central 

    Google Scholar 

47. Escribano, P. & Guinea, J. Fluconazole-resistant Candida parapsilosis: a new emerging threat in the fungi arena. Front. Fungal Bio. 3, 1010782 (2022).

    Google Scholar 

48. Cuenca-Estrella, M. et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin. Microbiol. Infect. 18, 9–18 (2012).

    CAS 

    Google Scholar 

49. Pappas, P. G. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin. Infect. Dis. 62, E1–E50 (2016).

    Google Scholar 

50. Rogers, T. R. et al. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. J. Antimicrob. Chemother. 77, 2053–2073 (2022).

    CAS 
    PubMed Central 

    Google Scholar 

51. Branco, J., Miranda, I. M. & Rodrigues, A. G. Candida parapsilosis virulence and antifungal resistance mechanisms: a comprehensive review of key determinants. J. Fungi 9, 80 (2023).

    CAS 

    Google Scholar 

52. Martini, C. et al. Prevalence and clonal distribution of azole-resistant Candida parapsilosis isolates causing bloodstream infections in a large Italian hospital. Front. Cell Infect. Microbiol. 10, 232 (2020).

    CAS 
    PubMed Central 

    Google Scholar 

53. Alcoceba, E. et al. Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain. Clin. Microbiol. Infect. 28, 1113–1119 (2022).

    CAS 

    Google Scholar 

54. Guinea, J. et al. Whole genome sequencing confirms Candida albicans and Candida parapsilosis microsatellite sporadic and persistent clones causing outbreaks of candidemia in neonates. Med. Mycol. 60, myab068 (2021).

    Google Scholar 

55. Xia, J., Huang, W., Lu, F., Li, M. & Wang, B. Comparative analysis of epidemiological and clinical characteristics between invasive Candida infection versus colonization in critically ill patients in a tertiary hospital in Anhui, China. Infect. Drug Resist. 15, 3905–3918 (2022).

    PubMed Central 

    Google Scholar 

56. Liu, Y., Kang, M., Ye, H., Zong, Z. & Lv, X. Analysis on clinical characteristics and drug resistance of Candida parapsilosis bloodstream infections in West China Hospital, China, from 2012 to 2015. J. Mycol. Med. 28, 222–226 (2018).

    CAS 

    Google Scholar 

57. Kimura, M. et al. Micafungin breakthrough fungemia in patients with hematological disorders. Antimicrob. Agents Chemother. 62, e02183-17 (2018).

    PubMed Central 

    Google Scholar 

58. Kimura, M. et al. Factors associated with breakthrough fungemia caused by Candida, Trichosporon, or Fusarium species in patients with hematological disorders. Antimicrob. Agents Chemother. 66, e0208121 (2022).

    Google Scholar 

59. Davari, A. et al. Echinocandin resistance in Candida parapsilosis sensu stricto: role of alterations in CHS3, FKS1 and Rho gene expression. J. Glob. Antimicrob. Resist. 22, 685–688 (2020).

    Google Scholar 

60. Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D. & Perlin, D. S. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52, 2305–2312 (2008).

    CAS 
    PubMed Central 

    Google Scholar 

61. Zhai, B. L. et al. Echinocandin heteroresistance causes prophylaxis failure and facilitates breakthrough Candida parapsilosis infection. Preprint at medRxiv https://doi.org/10.1101/2022.05.29.22275734 (2022).

62. Ricotta, E. E. et al. Invasive candidiasis species distribution and trends, United States, 2009–2017. J. Infect. Dis. 223, 1295–1302 (2021).

    Google Scholar 

63. Hirayama, T. et al. Virulence assessment of six major pathogenic Candida species in the mouse model of invasive candidiasis caused by fungal translocation. Sci. Rep. 10, 3814 (2020).

    CAS 
    PubMed Central 

    Google Scholar 

64. Intra, J., Sala, M. R., Brambilla, P., Carcione, D. & Leoni, V. Prevalence and species distribution of microorganisms isolated among non-pregnant women affected by vulvovaginal candidiasis: a retrospective study over a 20 year-period. J. Mycol. Med. 32, 101278 (2022).

    Google Scholar 

65. Makanjuola, O., Bongomin, F. & Fayemiwo, S. A. An update on the roles of non-albicans Candida species in vulvovaginitis. J. Fungi 4, 121 (2018).

    CAS 

    Google Scholar 

66. Moreira, D. et al. Difference between the profiles presented by yeasts that colonize the vaginal mucosa or cause primary or recurrent candidiasis. Mycopathologia 186, 411–421 (2021).

    CAS 

    Google Scholar 

67. Nash, A. K. et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome 5, 153 (2017).

    PubMed Central 

    Google Scholar 

68. Rao, C. et al. Multi-kingdom ecological drivers of microbiota assembly in preterm infants. Nature 591, 633–638 (2021).

    CAS 
    PubMed Central 

    Google Scholar 

69. Martino, C. et al. Microbiota succession throughout life from the cradle to the grave. Nat. Rev. Microbiol. 20, 707–720 (2022).

    CAS 

    Google Scholar 

70. Kondori, N. et al. Candida species as commensal gut colonizers: a study of 133 longitudinally followed Swedish infants. Med. Mycol. 58, 485–492 (2020). This article reports fungal gut colonization patterns of healthy Swedish neonates during the first months of life, and how birth mode and lifestyle factors influence yeast colonization.

    CAS 

    Google Scholar 

71. Ward, T. L. et al. Development of the human mycobiome over the first month of life and across body sites. mSystems 3, e00140-17 (2018).

    PubMed Central 

    Google Scholar 

72. James, S. A. et al. Preterm infants harbour a rapidly changing mycobiota that includes Candida pathobionts. J. Fungi 6, 273 (2020).

    Google Scholar 

73. Gonia, S. et al. Candida parapsilosis protects premature intestinal epithelial cells from invasion and damage by Candida albicans. Front. Pediatr. 5, 54 (2017).

    PubMed Central 

    Google Scholar 

74. Hamzavi, S. S. et al. Changing face of Candida colonization pattern in pediatric patients with hematological malignancy during repeated hospitalizations, results of a prospective observational study (2016–2017) in Shiraz, Iran. BMC Infect. Dis. 19, 759 (2019).

    PubMed Central 

    Google Scholar 

75. Geros-Mesquita, A. et al. Oral Candida albicans colonization in healthy individuals: prevalence, genotypic diversity, stability along time and transmissibility. J. Oral. Microbiol. 12, 1820292 (2020).

    CAS 
    PubMed Central 

    Google Scholar 

76. Benedict, K. et al. Neonatal and pediatric candidemia: results from population-based active laboratory surveillance in four US locations, 2009–2015. J. Pediatr. Infect. Dis. Soc. 7, e78–e85 (2018).

    Google Scholar 

77. Lee, J. et al. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. BMC Pediatr. 16, 67 (2016).

    PubMed Central 

    Google Scholar 

78. Duzgol, M. et al. Evaluation for metastatic Candida focus and mortality at Candida-associated catheter-related bloodstream infections at the pediatric hematology–oncology patients. J. Pediatr. Hematol. Oncol. 44, E643–E648 (2022).

    CAS 

    Google Scholar 

79. Karaagac, A. T., Savluk, O. F. & Yildirim, A. I. A 5-year analysis of Candida bloodstream infections in the paediatric cardiovascular surgery ICU of a tertiary care centre. Cardiol. Young 33, 301–305 (2022).

    Google Scholar 

80. Dotis, J., Prasad, P. A., Zaoutis, T. & Roilides, E. Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children. Pediatr. Infect. Dis. J. 31, 557–560 (2012).

    PubMed Central 

    Google Scholar 

81. Weimer, K. E. D., Smith, P. B., Puia-Dumitrescu, M. & Aleem, S. Invasive fungal infections in neonates: a review. Pediatr. Res. 91, 404–412 (2022).

    CAS 

    Google Scholar 

82. Cordeiro, R. A. et al. Phenotype-driven strategies for screening Candida parapsilosis complex for molecular identification. Braz. J. Microbiol. 49, 193–198 (2018).

    CAS 
    PubMed Central 

    Google Scholar 

83. Zhao, Y. et al. Yeast identification by sequencing, biochemical kits, MALDI-TOF MS and rep-PCR DNA fingerprinting. Med. Mycol. 56, 816–827 (2018).

    CAS 

    Google Scholar 

84. Vecchione, A. et al. Comparative evaluation of six chromogenic media for presumptive yeast identification. J. Clin. Pathol. 70, 1074–1078 (2017).

    CAS 

    Google Scholar 

85. Sasoni, N. et al. Candida auris and some Candida parapsilosis strains exhibit similar characteristics on CHROMagar™ Candida Plus. Med. Mycol. 8, myac062 (2022).

    Google Scholar 

86. Arendrup, M. C. et al. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clin. Microbiol. Infect. 26, 1464–1472 (2020). This review discusses the importance and implications of breakpoints for antifungal resistance testing and explains the reasoning behind the revision of echinocandin breakpoints for C. parapsilosis, which now classifies wild-type isolates as susceptible instead of intermediate.

    CAS 

    Google Scholar 

87. Mikulska, M. et al. Lower sensitivity of serum (1,3)-β-d-glucan for the diagnosis of candidaemia due to Candida parapsilosis. Clin. Microbiol. Infect. 22, e645–e648 (2016).

    Google Scholar 

88. Chiotos, K. et al. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12). J. Antimicrob. Chemother. 71, 3536–3539 (2016).

    CAS 
    PubMed Central 

    Google Scholar 

89. Brüggemann, R. J., Jensen, G. M. & Lass-Flörl, C. Liposomal amphotericin B—the past. J. Antimicrob. Chemother. 77, ii3–ii10 (2022).

    PubMed Central 

    Google Scholar 

90. Kontoyiannis, D. P. et al. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: analysis of pooled data from six prospective clinical studies. Mycoses 60, 663–667 (2017).

    CAS 

    Google Scholar 

91. Qin, J. L., Yang, H., Shan, Z. M., Jiang, L. Z. & Zhang, Q. X. Clinical efficacy and safety of antifungal drugs for the treatment of Candida parapsilosis infections: a systematic review and network meta-analysis. J. Med. Microbiol. 70, 001434 (2021).

    PubMed Central 

    Google Scholar 

92. Lass-Flörl, C. et al. Clinical usefulness of susceptibility breakpoints for yeasts in the treatment of candidemia: a noninterventional study. J. Fungi 6, 76 (2020).

    Google Scholar 

93. Hoenigl, M. et al. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin. Investig. Drugs 31, 795–812 (2022).

    CAS 
    PubMed Central 

    Google Scholar 

94. Diaz-Garcia, J. et al. Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance and absence of Candida auris. J. Antimicrob. Chemother. 77, 3102–3109 (2022).

    CAS 

    Google Scholar 

95. Hoenigl, M. et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 81, 1703–1729 (2021).

    CAS 
    PubMed Central 

    Google Scholar 

96. Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R. & Castanheira, M. Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018). Antimicrob. Agents Chemother. 64, e00099-20 (2020).

    PubMed Central 

    Google Scholar 

97. Vila, T., Ishida, K., Seabra, S. H. & Rozental, S. Miltefosine inhibits Candida albicans and non-albicans Candida spp. biofilms and impairs the dispersion of infectious cells. Int. J. Antimicrob. Agents 48, 512–520 (2016).

    CAS 

    Google Scholar 

98. Bergin, S. A. et al. Systematic analysis of copy number variations in the pathogenic yeast Candida parapsilosis identifies a gene amplification in RTA3 that is associated with drug resistance. mBio 13, e0177722 (2022).

    Google Scholar 

99. Yamin, D. et al. Global prevalence of antifungal-resistant Candida parapsilosis: a systematic review and meta-analysis. Trop. Med. Infect. Dis. 7, 188 (2022).

    PubMed Central 

    Google Scholar 

100. Cornely, O. A. et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18, 19–37 (2012).

     CAS 

     Google Scholar 

101. Marcos-Zambrano, L. J. et al. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect. Clin. Microbiol. Infect. 26, 1589–1592 (2020).

     CAS 

     Google Scholar 

102. Arendrup, M. C., Chowdhary, A., Astvad, K. M. T. & Jorgensen, K. M. APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method. Antimicrob. Agents Chemother. 62, e01225-18 (2018).

     PubMed Central 

     Google Scholar 

103. Siopi, M. et al. Pan-echinocandin resistant C. parapsilosis harboring an F652S Fks1 alteration in a patient with prolonged echinocandin therapy. J. Fungi 8, 931 (2022).

     Google Scholar 

104. Fu, L. W. et al. Different efficacies of common disinfection methods against Candida auris and other Candida species. J. Infect. Public Health 13, 730–736 (2020).

     Google Scholar 

105. Kan, B. et al. Cellular metabolism constrains innate immune responses in early human ontogeny. Nat. Commun. 9, 4822 (2018).

     PubMed Central 

     Google Scholar 

106. Hemedez, C. et al. Pathology of neonatal non-albicans candidiasis: autopsy study and literature review. Pediatr. Dev. Pathol. 22, 98–105 (2019).

     Google Scholar 

107. Garcia-Gamboa, R. et al. The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects. J. Hum. Nutr. Diet. 34, 645–655 (2021).

     Google Scholar 

108. Brilhante, R. S. N. et al. Exposure of Candida parapsilosis complex to agricultural azoles: an overview of the role of environmental determinants for the development of resistance. Sci. Total Environ. 650, 1231–1238 (2019).

     CAS 

     Google Scholar 

109. Lockhart, S. R. et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 64, 134–140 (2017).

     CAS 

     Google Scholar 

110. Chowdhary, A. et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob. Chemother. 73, 891–899 (2018).

     CAS 

     Google Scholar 

111. Rybak, J. M. et al. Delineation of the direct contribution of Candida auris ERG11 mutations to clinical triazole resistance. Microbiol. Spectr. 9, e0158521 (2021).

     Google Scholar 

112. Fekkar, A. et al. Hospital outbreak of fluconazole-resistant Candida parapsilosis: arguments for clonal transmission and long-term persistence. Antimicrob. Agents Chemother. 95, e02036-20 (2023). This article compares azole-susceptible clinical C. parapsilosis isolates and shows that strains harbouring the Y132F amino acid substitution are most likely to be involved in clustered and invasive infections.

     Google Scholar 

113. Mesini, A. et al. Changing epidemiology of candidaemia: increase in fluconazole-resistant Candida parapsilosis. Mycoses 63, 361–368 (2020).

     CAS 

     Google Scholar 

114. Magobo, R. E., Lockhart, S. R. & Govender, N. P. Fluconazole-resistant Candida parapsilosis strains with a Y132F substitution in the ERG11 gene causing invasive infections in a neonatal unit, South Africa. Mycoses 63, 471–477 (2020).

     CAS 

     Google Scholar 

115. O’Brien, C. E. et al. Identification of a novel Candida metapsilosis isolate reveals multiple hybridization events. G3 12, jkab367 (2022).

     Google Scholar 

116. Arastehfar, A. et al. The quiet and underappreciated rise of drug-resistant invasive fungal pathogens. J. Fungi 6, 138 (2020). This study updates the various molecular mechanisms underlying antifungal drug resistance in Candida and Aspergillus species.

     CAS 

     Google Scholar 

117. Papp, C. et al. Triazole evolution of Candida parapsilosis results in cross-resistance to other antifungal drugs, influences stress responses, and alters virulence in an antifungal drug-dependent manner. mSphere 5, e00821-20 (2020).

     PubMed Central 

     Google Scholar 

118. Pfaller, M. A., Carvalhaes, C. G., DeVries, S., Huband, M. D. & Castanheira, M. Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017–2019. Diagn. Microbiol. Infect. Dis. 102, 115627 (2022).

     CAS 

     Google Scholar 

119. Prigitano, A. et al. ICU environmental surfaces are a reservoir of fungi: species distribution in northern Italy. J. Hosp. Infect. 123, 74–79 (2022).

     CAS 

     Google Scholar 

120. Arastehfar, A. et al. Molecular identification, genotypic diversity, antifungal susceptibility, and clinical outcomes of infections caused by clinically underrated yeasts, Candida orthopsilosis, and Candida metapsilosis: an Iranian multicenter study (2014–2019). Front. Cell Infect. Microbiol. 9, 264 (2019).

     CAS 
     PubMed Central 

     Google Scholar 

121. Moreno-Martinez, A. E. et al. High biofilm formation of non-smooth Candida parapsilosis correlates with increased incorporation of GPI-modified wall adhesins. Pathogens 10, 493 (2021).

     CAS 
     PubMed Central 

     Google Scholar 

122. Ramos-Martinez, A. et al. Epidemiology and prognosis of candidaemia in elderly patients. Mycoses 60, 808–817 (2017).

     CAS 

     Google Scholar 

123. Arsic Arsenijevic, V. et al. Candida bloodstream infections in Serbia: first multicentre report of a national prospective observational survey in intensive care units. Mycoses 61, 70–78 (2018).

     CAS 

     Google Scholar 

124. Posteraro, B. et al. Candidaemia in haematological malignancy patients from a SEIFEM study: epidemiological patterns according to antifungal prophylaxis. Mycoses 63, 900–910 (2020).

     CAS 

     Google Scholar 

125. Klingspor, L. et al. Epidemiology of fungaemia in Sweden: a nationwide retrospective observational survey. Mycoses 61, 777–785 (2018).

     CAS 

     Google Scholar 

126. Lausch, K. R. et al. Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment. Infect. Drug Resist. 11, 2449–2459 (2018).

     CAS 
     PubMed Central 

     Google Scholar 

127. Bretagne, S. et al. No impact of fuconazole to echinocandins replacement as first-line therapy on the epidemiology of yeast fungemia (hospital-driven active surveillance, 2004–2017, Paris, France). Front. Med. 8, 641965 (2021).

     Google Scholar 

128. Adam, K. M. et al. Trends of the epidemiology of candidemia in Switzerland: a 15-year FUNGINOS survey. Open Forum Infect. Dis. 8, ofab471 (2021).

     PubMed Central 

     Google Scholar 

129. Santolaya, M. E. et al. A prospective, multi-center study of Candida bloodstream infections in Chile. PLoS ONE 14, e0212924 (2019).

     CAS 
     PubMed Central 

     Google Scholar 

130. Cortes, J. A. et al. Risk factors for mortality in Colombian patients with candidemia. J. Fungi 7, 442 (2021).

     Google Scholar 

131. Rodrigues, D. K. B. et al. Antifungal susceptibility profile of Candida clinical isolates from 22 hospitals of Sao Paulo State, Brazil. Braz. J. Med. Biol. Res. 54, e10928 (2021).

     CAS 
     PubMed Central 

     Google Scholar 

132. Toda, M. et al. Population-based active surveillance for culture-confirmed candidemia—four sites, United States, 2012–2016. MMWR Surveill. Summ. 68, 1–15 (2019).

     PubMed Central 

     Google Scholar 

133. Kakeya, H. et al. National trends in the distribution of Candida species causing candidemia in Japan from 2003 to 2014. Med. Mycol. J. 59, E19–E22 (2018).

     Google Scholar 

134. Xiao, M. et al. Five-year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. J. Clin. Microbiol. 56, e00577-18 (2018).

     PubMed Central 

     Google Scholar 

135. Vasilyeva, N. V. et al. Etiology of invasive candidosis agents in Russia: a multicenter epidemiological survey. Front. Med. 12, 84–91 (2018).

     CAS 

     Google Scholar 

136. Kord, M. et al. Epidemiology of yeast species causing bloodstream infection in Tehran, Iran (2015–2017); superiority of 21-plex PCR over the Vitek 2 system for yeast identification. J. Med. Microbiol. 69, 712–720 (2020).

     CAS 
     PubMed Central 

     Google Scholar 

137. Dogan, O. et al. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: a multicentre observational study by the Turkish Fungal Infections Study Group. Int. J. Antimicrob. Agents 56, 105992 (2020).

     CAS 

     Google Scholar 

138. Alobaid, K. et al. Epidemiology of candidemia in Kuwait: a nationwide, population-based study. J. Fungi 7, 673 (2021).

     CAS 

     Google Scholar 

139. Ranjbar-Mobarake, M., Nowroozi, J., Badiee, P., Mostafavi, S. N. & Mohammadi, R. Cross-sectional study of candidemia from Isfahan, Iran: etiologic agents, predisposing factors, and antifungal susceptibility testing. J. Res. Med. Sci. 26, 107 (2021).

     CAS 
     PubMed Central 

     Google Scholar 

140. Reda, N. M., Hassan, R. M., Salem, S. T. & Yousef, R. H. A. Prevalence and species distribution of Candida bloodstream infection in children and adults in two teaching university hospitals in Egypt: first report of Candida kefyr. Infection 51, 389–395 (2023).

     Google Scholar 

141. Kutlu, M. et al. Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey. Eur. J. Clin. Microbiol. Infect. Dis. 41, 597–607 (2022).

     Google Scholar 

142. Peman, J. & Ruiz-Gaitan, A. Candidemia from urinary tract source: the challenge of candiduria. Hosp. Pract. 46, 243–245 (2018).

     Google Scholar 

143. Levallois, J. et al. Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center. Int. J. Infect. Dis. 16, E41–E43 (2012).

     Google Scholar 

144. Sobel, J. D. & Suprapaneni, S. Candida parapsilosis vaginal infection—a new site of azole drug resistance. Curr. Infect. Dis. Rep. 20, 43 (2018).

     CAS 

     Google Scholar 

145. Toth, R., Toth, A., Vagvolgyi, C. & Gacser, A. Candida parapsilosis secreted lipase as an important virulence factor. Curr. Protein Pept. Sci. 18, 1043–1049 (2017).

     CAS 

     Google Scholar 

146. Aboutalebian, S. et al. Molecular epidemiology of otomycosis in Isfahan revealed a large diversity in causative agents. J. Med. Microbiol. 68, 918–923 (2019).

     CAS 

     Google Scholar 

147. Fich, F., Abarzua-Araya, A., Perez, M., Nauhm, Y. & Leon, E. Candida parapsilosis and Candida guillermondii: emerging pathogens in nail candidiasis. Indian. J. Dermatol. 59, 24–29 (2014).

     PubMed Central 

     Google Scholar 

148. Jain, A. G., Guan, J. & D’Souza, J. Candida parapsilosis: an unusual cause of infective endocarditis. Cureus 10, e3553 (2018).

     PubMed Central 

     Google Scholar 

149. Warris, A. et al. Etiology and outcome of candidemia in neonates and children in Europe: an 11-year multinational retrospective study. Pediatr. Infect. Dis. J. 39, 114–120 (2020).

     Google Scholar 

150. Trevijano-Contador, N. et al. Global emergence of resistance to fluconazole and voriconazole in Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic. Open Forum Infect. Dis. 9, ofac605 (2022).

     PubMed Central 

     Google Scholar 

151. Branco, J. et al. Clinical azole cross-resistance in Candida parapsilosis is related to a novel MRR1 gain-of-function mutation. Clin. Microbiol. Infect. 28, e1655–e1658 (2022).

     Google Scholar 

152. Kim, T. Y. et al. Evolution of fluconazole resistance mechanisms and clonal types of Candida parapsilosis isolates from a tertiary care hospital in South Korea. Antimicrob. Agents Chemother. 66, e0088922 (2022).

     Google Scholar 

153. Papp, C. et al. Echinocandin-induced microevolution of Candida parapsilosis influences virulence and abiotic stress tolerance. mSphere 3, e00547-18 (2018).

     PubMed Central 

     Google Scholar 

154. Ning, Y. et al. Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China. Emerg. Microbes Infect. 12, 2153086 (2022).

     PubMed Central 

     Google Scholar 

155. Arastehfar, A. et al. Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge? J. Antimicrob. Chemother. 76, 418–422 (2021).

     CAS 

     Google Scholar 

156. Marti-Carrizosa, M., Sanchez-Reus, F., March, F., Canton, E. & Coll, P. Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 59, 3570–3573 (2015).

     CAS 
     PubMed Central 

     Google Scholar 

157. Morio, F. et al. Precise genome editing using a CRISPR–Cas9 method highlights the role of CoERG11 amino acid substitutions in azole resistance in Candida orthopsilosis. J. Antimicrob. Chemother. 74, 2230–2238 (2019).

     CAS 

     Google Scholar 

158. Rizzato, C. et al. CoERG11 A395T mutation confers azole resistance in Candida orthopsilosis clinical isolates. J. Antimicrob. Chemother. 73, 1815–1822 (2018).

     CAS 

     Google Scholar 

159. Yang, F. et al. Aneuploidy underlies tolerance and cross-tolerance to drugs in Candida parapsilosis. Microbiol. Spectr. 9, e0050821 (2021).

     Google Scholar 

160. Pfaller, M. A. et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J. Clin. Microbiol. 50, 2040–2046 (2012).

     CAS 
     PubMed Central 

     Google Scholar 

Download references